Egypt Immuno-Oncology Research Review Issue 2

In this issue:
  -  First-line atezolizumab/ vemurafenib/cobimetinib for unresectable BRAF V600+ve melanoma
  -  Anti-PD1 checkpoint inhibitors for acral melanoma
  -  Nivolumab vs. everolimus in advanced renal cell carcinoma
  -  Predicting outcomes and immune-related adverse events in PD1 inhibitor-treated advanced NSCLC
  -  Outcomes associated with immune-related adverse events in nivolumab-treated metastatic NSCLC
  -  Toxicities, body composition and QOL after anti-PD1/PD-L1 therapy
  -  Sarcomatoid renal cell carcinoma: redefining first-line treatment
  -  Neoadjuvant nivolumab for resectable Merkel cell carcinoma
  -  Combined PD-L1 and CTLA-4 inhibition for CRC
  -  Immune checkpoint inhibitor rechallenge after immunerelated adverse events

Download PDF Subscribe